BIO-Europe 2026: Finland based Kasvu Therapeutics is trying to induce the benefits of psychedelics without the hallucination aspect by modulating TrkB receptors in the brain
Co-Founder & CEO Jami Mandelin describes the scientific rationale behind this approach, which they believe is a novel breakthrough. The company recently announced a €30M series A.
Coverage brought to you by










.png)
